Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALG-125755 in Healthy Volunteers and Chronic Hepatitis B
NCT05561530Phase 1Terminated
- Sponsor
- Aligos Therapeutics
- Start
- Oct 2022
- Primary completion
- Jun 2023
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ALG-125755 with Placebo (2 arms). Primary endpoint: Incidence and severity of treatment emergent adverse events up to 616 days. Started Oct 2022; status: terminated.
02
Drugs
ALG-125755
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT05561530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05561530.